{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:42:03Z","timestamp":1788432123984,"version":"build-2803163510"},"reference-count":107,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Sci.","Medical Sciences"],"abstract":"<jats:p>Atherosclerotic cardiovascular disease (CVD) remains a leading cause of worldwide morbidity and mortality, despite well-established\/effective pharmacological therapies. A substantial component of the residual risk is inflammatory. The importance of inflammation and immune mediators in the pathophysiology has been recognised over the past two decades and, importantly, treatment with percutaneous coronary intervention (PCI) also results in an inflammatory response and associated adverse outcomes. Multiple biochemical pathways have been implicated with various identified biomarkers, such as high-sensitivity C-reactive protein which is now recognised as a marker of cardiovascular risk. Proteins such as interleukins (IL) IL-1 and IL-6 or larger protein complexes such as the NLRP3 inflammasome all play a key role in both the pathophysiology of atherosclerosis and inflammation relating to PCI. This knowledge has led to advances in pharmacological therapies and multiple pre-clinical and clinical trials, but to date, colchicine is the only treatment with sufficiently robust evidence from large-scale clinical trials to be recommended in multinational guidelines. Other therapies at present lack this level of evidence, and identification of other potential therapies is an important next step in treating inflammation post-PCI. Furthermore, the potential routine use of colchicine periprocedurally for PCI and its biochemical and clinical effects in this context are not yet fully established, requiring further investigation to identify its effect on specific inflammatory mediators and whether this translates to clinical outcomes.<\/jats:p>","DOI":"10.3390\/medsci14040430","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:15:56Z","timestamp":1785140156000},"page":"430","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inflammation and Immune Mediators in the Context of Atherosclerotic Cardiovascular Disease and Percutaneous Coronary Intervention: Implications for Therapeutics"],"prefix":"10.3390","volume":"14","author":[{"given":"Karthik","family":"Chandrasekharan","sequence":"first","affiliation":[{"name":"Department of Cardiology, Norfolk and Norwich University Hospital, Norwich NR4 7UY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratyasha","family":"Saha","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Merinopoulos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Norfolk and Norwich University Hospital, Norwich NR4 7UY, UK"},{"name":"Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6395-2389","authenticated-orcid":false,"given":"Simon","family":"Eccleshall","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Norfolk and Norwich University Hospital, Norwich NR4 7UY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0427-8678","authenticated-orcid":false,"given":"James G. W.","family":"Smith","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4005-7752","authenticated-orcid":false,"given":"Vassilios S.","family":"Vassiliou","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"ref_1","unstructured":"(2025, December 23). Death Registration Summary Statistics, England and Wales\u2014Office for National Statistics, Available online: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/deaths\/articles\/deathregistrationsummarystatisticsenglandandwales\/2022."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/ehjqcco\/qcaf011","article-title":"Economic Burden of Cardiovascular Disease in the United Kingdom","volume":"11","author":"Shih","year":"2025","journal-title":"Eur. Heart J. Qual. Care Clin. Outcomes"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41419-024-07166-8","article-title":"Inflammation in Atherosclerosis: Pathophysiology and Mechanisms","volume":"15","author":"Ajoolabady","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"III\u201315","DOI":"10.1161\/01.CIR.0000131513.33892.5b","article-title":"New Risk Factors for Atherosclerosis and Patient Risk Assessment","volume":"109","author":"Fruchart","year":"2004","journal-title":"Circulation"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1016\/j.ymthe.2022.08.024","article-title":"Anti-Atherosclerotic Therapies: Milestones, Challenges, and Emerging Innovations","volume":"30","author":"Hetherington","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tucker, B., Vaidya, K., Cochran, B.J., and Patel, S. (2021). Inflammation during Percutaneous Coronary Intervention\u2014Prognostic Value, Mechanisms and Therapeutic Targets. Cells, 10.","DOI":"10.3390\/cells10061391"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"History of Discovery: Inflammation in Atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014An Inflammatory Disease","volume":"340","author":"Ross","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.immuni.2013.06.009","article-title":"Immune Effector Mechanisms Implicated in Atherosclerosis: From Mice to Humans","volume":"38","author":"Libby","year":"2013","journal-title":"Immunity"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4244\/EIJ-D-23-00606","article-title":"Targeting Inflammation in Atherosclerosis: Overview, Strategy and Directions","volume":"20","author":"Waksman","year":"2024","journal-title":"EuroIntervention"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women","volume":"342","author":"Ridker","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men","volume":"336","author":"Ridker","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1161\/01.ATV.0000079512.66448.1D","article-title":"C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease","volume":"23","author":"Luc","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and Cholesterol as Predictors of Cardiovascular Events among Patients Receiving Statin Therapy: A Collaborative Analysis of Three Randomised Trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 Inflamasomes Are Required for Atherogenesis and Activated by Cholesterol Crystals That Form Early in Disease","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rajam\u00e4ki, K., Lappalainen, J., O\u00f6rni, K., V\u00e4lim\u00e4ki, E., Matikainen, S., Kovanen, P.T., and Eklund, K.K. (2010). Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0011765"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kapellos, T.S., Bonaguro, L., Gem\u00fcnd, I., Reusch, N., Saglam, A., Hinkley, E.R., and Schultze, J.L. (2019). Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.02035"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cardiores.2005.01.008","article-title":"Interleukin-1 Plays a Major Role in Vascular Inflammation and Atherosclerosis in Male Apolipoprotein E-Knockout Mice","volume":"66","author":"Kwak","year":"2005","journal-title":"Cardiovasc. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1161\/hc3901.096721","article-title":"Expression of Interleukin-18 in Human Atherosclerotic Plaques and Relation to Plaque Instability","volume":"104","author":"Mallat","year":"2001","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ling, Y., Weng, H., and Tang, S. (2021). The Relationship between IL-6 Levels and the Angiographic Severity of Coronary Artery Disease Following Percutaneous Coronary Intervention in Acute Coronary Syndrome Patients. BMC Cardiovasc. Disord., 21.","DOI":"10.1186\/s12872-021-02406-7"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1161\/ATVBAHA.118.310945","article-title":"Association of Total and Differential Leukocyte Counts With Cardiovascular Disease and Mortality in the UK Biobank","volume":"38","author":"Welsh","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jacc.2013.07.043","article-title":"Monocytes in Coronary Artery Disease and Atherosclerosis: Where Are We Now?","volume":"62","author":"Ghattas","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Kozlov, S., Riazantseva, T., Melnikov, I., Okhota, S., Vasenkova, V., Saburova, O., Avtaeva, Y., Guria, K., Prokofieva, L., and Gabbasov, Z. (2025). Monocytes\/Macrophages and Atherogenesis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262210962"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1182\/blood-2010-12-326355","article-title":"Gene Expression Profiling Reveals the Defining Features of the Classical, Intermediate, and Nonclassical Human Monocyte Subsets","volume":"118","author":"Wong","year":"2011","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1161\/CIRCGENETICS.111.960385","article-title":"Elevated CD14++CD16\u2212 Monocytes Predict Cardiovascular Events","volume":"5","author":"Berg","year":"2012","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.yjmcc.2019.01.002","article-title":"Circulating CD14+CD16\u2212 Classical Monocytes Do Not Associate with a Vulnerable Plaque Phenotype, and Do Not Predict Secondary Events in Severe Atherosclerotic Patients","volume":"127","author":"Meeuwsen","year":"2019","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/ATVBAHA.118.311022","article-title":"Human Monocyte Heterogeneity as Revealed by High-Dimensional Mass Cytometry","volume":"39","author":"Hamers","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jacc.2012.07.019","article-title":"CD14++CD16+ Monocytes Independently Predict Cardiovascular Events","volume":"60","author":"Rogacev","year":"2012","journal-title":"JACC"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2017.09.032","article-title":"Shift of Monocyte Subsets along Their Continuum Predicts Cardiovascular Outcomes","volume":"266","author":"Cappellari","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"131780","DOI":"10.1016\/j.ijcard.2024.131780","article-title":"Intermediate Monocytes Are Associated with the First Major Adverse Cardiovascular Event in Patients with Stable Coronary Artery Disease","volume":"400","author":"Dregoesc","year":"2024","journal-title":"Int. J. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.atherosclerosis.2010.05.004","article-title":"Association of Monocyte Subsets with Vulnerability Characteristics of Coronary Plaques as Assessed by 64-Slice Multidetector Computed Tomography in Patients with Stable Angina Pectoris","volume":"212","author":"Kashiwagi","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1161\/01.CIR.102.24.2919","article-title":"Transfer of CD4(+) T Cells Aggravates Atherosclerosis in Immunodeficient Apolipoprotein E Knockout Mice","volume":"102","author":"Zhou","year":"2000","journal-title":"Circulation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/MCA.0000000000001198","article-title":"Inflammation in Coronary Artery Disease-Clinical Implications of Novel HDL-Cholesterol\u2013Related Inflammatory Parameters as Predictors","volume":"34","author":"Guo","year":"2023","journal-title":"Coron. Artery Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1161\/CIRCRESAHA.117.312340","article-title":"Alternative Splicing of FOXP3 Controls Regulatory T Cell Effector Functions and Is Associated With Human Atherosclerotic Plaque Stability","volume":"122","author":"Joly","year":"2018","journal-title":"Circ. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jacbts.2021.01.006","article-title":"B Cells in Atherosclerosis","volume":"6","author":"Pattarabanjird","year":"2021","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1378\/chest.07-1693","article-title":"Effects of Percutaneous Coronary Intervention on Peripheral Venous Blood Circulating Endothelial Cells and Plasma Indices of Endothelial Damage\/Dysfunction","volume":"132","author":"Boos","year":"2007","journal-title":"Chest"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10753-014-0018-8","article-title":"Role of Pre-Procedural C-Reactive Protein Level in the Prediction of Major Adverse Cardiac Events in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysisof Longitudinal Studies","volume":"38","author":"Bibek","year":"2015","journal-title":"Inflammation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1161\/01.ATV.0000037100.44766.5B","article-title":"Inflammation and Restenosis in the Stent Era","volume":"22","author":"Welt","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.23736\/S2724-5683.22.06091-4","article-title":"The Role of Inflammation in Percutaneous Coronary Intervention, from Balloon Angioplasty to Drug Eluting Stents","volume":"71","author":"Merinopoulos","year":"2023","journal-title":"Minerva Cardiol. Angiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e70757","DOI":"10.1002\/hsr2.70757","article-title":"Pre-Percutaneous Coronary Intervention C-Reactive Protein Levels and In-Stent Restenosis: A Systematic Review and Meta-Analysis","volume":"8","author":"Rai","year":"2025","journal-title":"Health Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e032300","DOI":"10.1161\/JAHA.122.032300","article-title":"Association of Periprocedural Inflammatory Activation With Increased Risk for Early Coronary Stent Thrombosis","volume":"13","author":"Krychtiuk","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e46763","DOI":"10.1097\/MD.0000000000046763","article-title":"Rapid Progression of Non-Culprit Vessels (NCVs) Post-PCI in Acute Myocardial Infarction: Causes and Current Research Status","volume":"105","author":"Li","year":"2026","journal-title":"Medicine"},{"key":"ref_43","first-page":"1937","article-title":"Breaking the Barrier: Unraveling the No-Reflow Phenomenon in Cardiovascular Medicine","volume":"106","author":"Howes","year":"2025","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.carrev.2008.01.003","article-title":"Association between C-Reactive Protein and Angiographic Restenosis after Bare Metal Stents: An Updated and Comprehensive Meta-Analysis of 2747 Patients","volume":"9","author":"Ferrante","year":"2008","journal-title":"Cardiovasc. Revasc Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ehj.2015.02.004","article-title":"The Inflammatory Response to Percutaneous Coronary Intervention Is Related to the Technique of Stenting and Not the Type of Stent","volume":"68","author":"Sakr","year":"2016","journal-title":"Egypt. Heart J."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Maestre-Luque, L.C., Gonzalez-Manzanares, R., Gallo, I., Hidalgo, F., Su\u00e1rez de Lezo, J., Romero, M., Espejo-Perez, S., Perez-Sanchez, C., Mart\u00ednez-Moreno, J.M., and Gonz\u00e1lez-Fernandez, R. (2026). Percutaneous Coronary Intervention for Chronic Total Occlusions Modulates Cardiac Hypoxic and Inflammatory Stress. J. Clin. Med., 15.","DOI":"10.3390\/jcm15020517"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000447558","article-title":"C-Reactive Protein and Inflammatory Cytokines during Percutaneous Coronary Intervention","volume":"53","author":"Wu","year":"2016","journal-title":"J. Vasc. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/eurheartj\/ehad486","article-title":"Inflammation in Acute Myocardial Infarction: The Good, the Bad and the Ugly","volume":"45","author":"Matter","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_49","first-page":"657025","article-title":"Pentraxin 3: A Novel Biomarker for Inflammatory Cardiovascular Disease","volume":"2012","author":"Inoue","year":"2012","journal-title":"Int. J. Vasc. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.atherosclerosis.2019.11.022","article-title":"Relationship of Systemic Pentraxin-3 Values with Coronary Plaque Components on Optical Coherence Tomography and Post-Percutaneous Coronary Intervention Outcomes in Patients with Stable Angina Pectoris","volume":"292","author":"Kimura","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/A:1026188200939","article-title":"Increase in Interleukin-6 in the First Hour after Coronary Stenting: An Early Marker of the Inflammatory Response","volume":"15","author":"Aggarwal","year":"2003","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/heart.84.1.83","article-title":"Interleukin 6 Expression in Coronary Circulation after Coronary Angioplasty as a Risk Factor for Restenosis","volume":"84","author":"Hojo","year":"2000","journal-title":"Heart"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.amjcard.2006.04.034","article-title":"Impact of Percutaneous Coronary Intervention on the Levels of Interleukin-6 and C-Reactive Protein in the Coronary Circulation of Subjects with Coronary Artery Disease","volume":"98","author":"Ramadan","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e001869","DOI":"10.1136\/openhrt-2021-001869","article-title":"High Levels of Interleukin-6 Are Associated with Final Infarct Size and Adverse Clinical Events in Patients with STEMI","volume":"8","author":"Shetelig","year":"2021","journal-title":"Open Heart"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0735-1097(03)80073-6","article-title":"Preprocedure Inflammatory State Predicts Periprocedural Myocardial Infarction after Elective Percutaneous Coronary Intervention: An EPIC Substudy","volume":"41","author":"Aronow","year":"2003","journal-title":"JACC"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jacc.2003.08.026","article-title":"Circulating Monocytes and In-Stent Neointima after Coronary Stent Implantation","volume":"43","author":"Fukuda","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/MCA.0000000000000301","article-title":"Association of Lymphocyte-to-Monocyte Ratio with the No-Reflow Phenomenon in Patients Who Underwent a Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction","volume":"26","author":"Kurtul","year":"2015","journal-title":"Coron. Artery Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/MCA.0000000000000848","article-title":"Predictive Accuracy of Lymphocyte-to-Monocyte Ratio and Monocyte-to-High-Density-Lipoprotein-Cholesterol Ratio in Determining the Slow Flow\/No-Reflow Phenomenon in Patients with Non-ST-Elevated Myocardial Infarction","volume":"31","author":"Kalyoncuoglu","year":"2020","journal-title":"Coron. Artery Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0002-9149(00)01159-0","article-title":"Comparison of Activation Process of Platelets and Neutrophils after Coronary Stent Implantation versus Balloon Angioplasty for Stable Angina Pectoris","volume":"86","author":"Inoue","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Merinopoulos, I., Bhalraam, U., Holmes, T., Tsampasian, V., Corballis, N., Gunawardena, T., Sawh, C., Maart, C., Wistow, T., and Ryding, A. (2023). Circulating Intermediate Monocytes CD14++CD16+ Are Increased after Elective Percutaneous Coronary Intervention. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0294746"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e19269","DOI":"10.1016\/j.heliyon.2023.e19269","article-title":"Association between NLRP3 Inflammasome and Periprocedural Myocardial Injury Following Elective PCI","volume":"9","author":"Chen","year":"2023","journal-title":"Heliyon"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"cvae088.137","DOI":"10.1093\/cvr\/cvae088.137","article-title":"Inflammasome Activation Dynamics within the First 24 Hours in Patients Treated with PCI for Myocardial Infarction Is Influenced by the Age of Patients, Preliminary Report","volume":"120","author":"Janiszewski","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e018993","DOI":"10.1161\/JAHA.120.018993","article-title":"Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention","volume":"10","author":"Vaidya","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s10753-024-02062-x","article-title":"Longitudinal Variations in Th and Treg Cells Before and After Percutaneous Coronary Intervention, and Their Intercorrelations and Prognostic Value in Acute Syndrome Patients","volume":"48","author":"Chen","year":"2025","journal-title":"Inflammation"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jacc.2018.12.083","article-title":"Targeting the Immune System in Atherosclerosis","volume":"73","author":"Zhao","year":"2019","journal-title":"JACC"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","article-title":"PCSK9 Inhibition and Inflammation: A Narrative Review","volume":"288","author":"Ruscica","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/rheumatology\/kead625","article-title":"Colchicine: The Good, the Bad, the Ugly and How to Minimize the Risks","volume":"63","author":"Stamp","year":"2023","journal-title":"Rheumatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine --- Update on Mechanisms of Action and Therapeutic Uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2017.12.027","article-title":"The NLRP3 Inflammasome and the Emerging Role of Colchicine to Inhibit Atherosclerosis-Associated Inflammation","volume":"269","author":"Celermajer","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Bulnes, J.F., Gonz\u00e1lez, L., Vel\u00e1squez, L., Orellana, M.P., Venturelli, P.M., and Mart\u00ednez, G. (2024). Role of Inflammation and Evidence for the Use of Colchicine in Patients with Acute Coronary Syndrome. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1356023"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/cpt.3394","article-title":"The Effect of Low-Dose Colchicine on the Phenotype and Function of Neutrophils and Monocytes in Patients with Chronic Coronary Artery Disease: A Double-Blind Randomized Placebo-Controlled Cross-Over Study","volume":"116","author":"Tercan","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/oby.23632","article-title":"Immunomodulatory Effects of Colchicine on Peripheral Blood Mononuclear Cell Subpopulations in Human Obesity: Data from a Randomized Controlled Trial","volume":"31","author":"Patel","year":"2023","journal-title":"Obesity"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"108854","DOI":"10.1016\/j.clim.2021.108854","article-title":"Distribution of Monocytes Subpopulations in the Peripheral Blood from Patients with Beh\u00e7et\u2019s Disease\u2014Impact of Disease Status and Colchicine Use","volume":"231","author":"Belem","year":"2021","journal-title":"Clin. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1093\/eurheartj\/ehaa659","article-title":"Time-to-Treatment Initiation of Colchicine and Cardiovascular Outcomes after Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)","volume":"41","author":"Bouabdallaoui","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in Acute Myocardial Infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in Patients with Chronic Coronary Disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and Safety of Low-Dose Colchicine in Patients with Coronary Disease: A Systematic Review and Meta-Analysis of Randomized Trials","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the Management of Acute Coronary Syndromes: Developed by the Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the Management of Chronic Coronary Syndromes: Developed by the Task Force for the Management of Chronic Coronary Syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","article-title":"Consensus Statement Regarding the Efficacy and Safety of Long-Term Low-Dose Colchicine in Gout and Cardiovascular Disease","volume":"135","author":"Robinson","year":"2022","journal-title":"Am. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/eurjpc\/zwaf302","article-title":"The Efficacy and Safety of Low Dose Colchicine in Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis","volume":"33","author":"Tucker","year":"2026","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e009992","DOI":"10.1161\/CIRCINTERVENTIONS.120.009992","article-title":"Colchicine to Prevent Periprocedural Myocardial Injury in Percutaneous Coronary Intervention: The COPE-PCI Pilot Trial","volume":"14","author":"Cole","year":"2021","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e008717","DOI":"10.1161\/CIRCINTERVENTIONS.119.008717","article-title":"Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: The COLCHICINE-PCI Randomized Trial","volume":"13","author":"Shah","year":"2020","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/FJC.0000000000001317","article-title":"Preprocedural Colchicine in Patients With Acute ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: A Randomized Controlled Trial (PodCAST-PCI)","volume":"80","author":"Hosseini","year":"2022","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_87","first-page":"75","article-title":"Review of Tocilizumab in the Treatment of Rheumatoid Arthritis","volume":"2","author":"Okuda","year":"2008","journal-title":"Biologics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a Single Dose of the Interleukin-6 Receptor Antagonist Tocilizumab on Inflammation and Troponin T Release in Patients with Non-ST-Elevation Myocardial Infarction: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction","volume":"77","author":"Broch","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1136\/heartjnl-2016-310875","article-title":"Effect of Interleukin-6 Inhibition on Coronary Microvascular and Endothelial Function in Myocardial Infarction","volume":"103","author":"Holte","year":"2017","journal-title":"Heart"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e015628","DOI":"10.1161\/JAHA.119.015628","article-title":"Novel Insights Into the Effects of Interleukin 6 Antagonism in Non\u2013ST-Segment\u2013Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform","volume":"9","author":"George","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 Inhibition with Ziltivekimab in Patients at High Atherosclerotic Risk (RESCUE): A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S767","DOI":"10.1016\/j.ekir.2024.11.1354","article-title":"WCN25-888 Design of the Zeus Trial: Interleukin 6 Inhibition with Ziltivekimab for Cardiovascular Protection in Chronic Kidney Disease","volume":"10","author":"Perkovic","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The Effect of Interleukin-1 Receptor Antagonist Therapy on Markers of Inflammation in Non-ST Elevation Acute Coronary Syndromes: The MRC-ILA Heart Study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/FJC.0000000000001635","article-title":"Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction: Secondary End Points From an International, Double-Blind, Randomized, Placebo-Controlled, Phase 2a Study","volume":"84","author":"Abbate","year":"2024","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-Dose Methotrexate for the Prevention of Atherosclerotic Events","volume":"380","author":"Ridker","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and Its Mechanisms of Action in Inflammatory Arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Forzano, I., Florimonte, D., Narciso, V., Canonico, M.E., Castiello, D.S., Manzi, L., Cristiano, S., Spinelli, A., Vallone, D.M., and D\u2019Alconzo, D. (2025). Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention. J. Clin. Med., 14.","DOI":"10.3390\/jcm14238334"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.immuni.2025.09.012","article-title":"Inflammation in Atherosclerosis: Lessons and Therapeutic Implications","volume":"58","author":"Libby","year":"2025","journal-title":"Immunity"},{"key":"ref_100","first-page":"e131","article-title":"Pharmacological Targeting of the CCL2\/CCR2 Axis for Atheroprotection: A Meta-Analysis of Preclinical Studies","volume":"42","author":"Asare","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Chen, P., and Li, X. (2024). NLRP3 Inflammasome in Atherosclerosis: Mechanisms and Targeted Therapies. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1430236"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jacbts.2024.12.012","article-title":"NLRP3 Inflammasome Inhibition by the Novel Bispecific Antibody InflamAb Attenuates Atherosclerosis in Apolipoprotein E\u2013Deficient Mice","volume":"10","author":"Delfos","year":"2025","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm1343","article-title":"Natural Regulatory T Cells Control the Development of Atherosclerosis in Mice","volume":"12","author":"Salomon","year":"2006","journal-title":"Nat. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s44161-025-00765-4","article-title":"Translating Nobel Prize-Winning Treg Cell Science into Cardiovascular Therapy","volume":"5","author":"Mallat","year":"2025","journal-title":"Nat. Cardiovasc. Res."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Schwab, R.D., Degaramo, D., Hong, S.J., Bi, X., Faruqi, A., Aguilar, W., Brookens, S.K., Keane, J.T., Liu, F., and Musunuru, K. (2025). OxLDL-Targeted Chimeric Antigen Receptor T Regulatory Cells Reduce Atherosclerotic Plaque Development. Circulation, 53.","DOI":"10.1101\/2025.01.24.634830"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/eurjpc\/zwaf026","article-title":"Impact of Sodium\u2013Glucose Cotransporter-2 Inhibitors on Heart Failure Outcomes in Cancer Patients and Survivors: A Systematic Review and Meta-Analysis","volume":"33","author":"Bhalraam","year":"2026","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Scisciola, L., Cataldo, V., Taktaz, F., Fontanella, R.A., Pesapane, A., Ghosh, P., Franzese, M., Puocci, A., De Angelis, A., and Sportiello, L. (2022). Anti-Inflammatory Role of SGLT2 Inhibitors as Part of Their Anti-Atherosclerotic Activity: Data from Basic Science and Clinical Trials. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.1008922"}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/4\/430\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:30:23Z","timestamp":1785141023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/4\/430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":107,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["medsci14040430"],"URL":"https:\/\/doi.org\/10.3390\/medsci14040430","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]}}}